Welcome to our dedicated page for Immuron news (Ticker: IMRN), a resource for investors and traders seeking the latest updates and insights on Immuron stock.
Immuron Limited develops and commercializes orally delivered targeted polyclonal antibodies for gastrointestinal infectious diseases. The Australian biopharmaceutical company uses a hyper-immune bovine colostrum platform and markets Travelan®, an over-the-counter product for travelers’ diarrhea and digestive tract protection, in Australia, the United States and Canada.
Recurring news covers Travelan sales by region, the Australian launch of ProIBS®, research funding and collaborations for enteric pathogens, and updates on clinical programs such as IMM-124E and IMM-529. Company announcements also discuss operating results, strategic updates, distribution expansion and investor conference presentations tied to its ASX and Nasdaq listings.
Immuron (NASDAQ: IMRN; ASX: IMC) announced that CEO Steven Lydeamore will present virtually at the Kalkine Media Webinar on Monday, 20 July 2026 at 12:30pm Australian Eastern Time. The accompanying slide deck is available on Immuron’s investor website.
According to Immuron, the company develops orally delivered targeted polyclonal antibodies for infectious diseases, led by Travelan (IMM‑124E) for travelers’ diarrhea, adjunctive candidate IMM‑529 for recurrent Clostridioides difficile infection, and distribution of ProIBS for irritable bowel syndrome in Australia and New Zealand.
Immuron reported unaudited FY26 global sales of Travelan of AUD$7.7 million, up 6% on the prior comparative period, with 2H FY26 sales of AUD$3.5 million (+7%) and 4Q FY26 sales of AUD$2.0 million (+2%). Australian FY26 sales reached AUD$5.8 million, up 10%, supported by digital and social media marketing, same store growth, new banner group stores and increased South East Asian travel.
In the USA, FY26 Travelan sales were AUD$1.8 million (+7%) or USD$1.2 million (+13%), aided by Amazon store improvements and expanded social media, partly offset by a stronger Australian dollar. Canada delivered FY26 sales of AUD$0.2 million (down 55%), but 2H sales rose over 1000% on pcp and 4Q sales increased 376% on pcp as brand awareness and in store promotions grew.
Immuron (NASDAQ: IMRN, ASX: IMC) engaged Pullan Consulting to secure a strategic partner for IMM-529, an oral polyclonal antibody candidate for Clostridioides difficile infection (CDI). IMM-529 has FDA-cleared IND 32095 and is Phase 2 trial–ready, with protocol, sites, principal investigator and drug product prepared.
The planned randomized, double-blind, placebo-controlled study will enroll up to 60 CDI patients to assess safety, tolerability and efficacy alongside standard of care. A Lumanity opportunity assessment projects base-case annual revenue of US$400M if IMM-529 proves efficacious and is positioned at first recurrence, with ~98,000 eligible patients.
Immuron (Nasdaq:IMRN) received a Flash Report from Emerging Growth Research on April 22, 2026, which maintained a Buy-Extended rating and raised the 12-month price target to $4.00 from $3.90.
Key facts: global product revenue of AUD $1.5 million in 3Q FY2026 (+16% YoY); Australia revenue +15% YoY; U.S. +1% YoY (AUD basis); Canada +82% QoQ; third product launched in Australia Dec 2025; IMM-529 cleared by FDA to proceed to Phase 2; Emerging Growth values enterprise at ~$33.3 million using a 6.22x EV/Revenue multiple.
Immuron (NASDAQ: IMRN) reported unaudited Q3 sales of AUD$1.5 million, up 16% on the prior comparative period, with YTD Mar 2026 sales of AUD$5.7 million up 7%.
By region: Australia Q3 AUD$0.9M (+15%; YTD AUD$4.2M +14%), USA Q3 AUD$0.5M (+1%; YTD AUD$1.3M +10%), Canada Q3 AUD$0.1M (Q3 +82% vs prior quarter; YTD AUD$0.1M -65%). Growth attributed to expanded digital marketing, promotions, new store listings and increased travel.
Immuron (Nasdaq:IMRN) reported first-half FY2026 results and a strategic update. Global product revenue was AUD $4.18 million, up ~5% year-over-year, with Australian revenue +13% and U.S. revenue +17%. Gross margin was 63.4% and net loss narrowed to AUD $(1.92) million.
The company raised ~AUD $7.3 million via an at-the-market facility, bringing cash to ~AUD $10.0 million and providing runway into 2027. FDA authorization was granted to proceed with a randomized Phase 2 trial for IMM-529; ProIBS® launched in Australia in December 2025.
Immuron (NASDAQ: IMRN) CEO Steven Lydeamore will present virtually at the Coffee Microcaps Conference on 5 March 2026 from 11:00–11:30am Australian Eastern Time. A slide deck is available on the company investor website and the presentation is scheduled as a 30-minute virtual session.
Immuron (NASDAQ: IMRN) reported H1 FY26 results and a strategic reset on Feb 25, 2026. Global H1 FY26 sales rose to AUD $4.2 million with U.S. sales up 17% YoY. Cash on hand is AUD $10.0 million, including AUD $7.3 million net raised at A$0.0803 average price. The company highlighted its Hyper-Immune platform, progress toward an end-of-Phase-2 meeting for IMM-124E, and FDA IND approval for IMM-529. Management said it will pursue partnerships to fund Travelan (IMM-124E) and IMM-529 clinical programs.
Immuron (Nasdaq:IMRN) reported first-half fiscal 2026 revenue of AUD$4.2 million for the six months ended December 31, 2025, a 5% increase year-over-year driven by Travelan sales in Australia and the U.S. Australian revenue rose 13% to AUD$3.3 million and U.S. revenue rose 17% to AUD$0.9 million; Canadian revenue declined due to distributor inventory dynamics.
The firm launched ProIBS in December 2025 in Australia and continues to invest in its polyclonal antibody platform and clinical-stage pipeline. Emerging Growth Research maintained a Buy-Extended rating and a $3.50 12-month price target, citing current product revenue, early commercial traction, and clinical potential while noting reliance on external capital to fund development.
Immuron (NASDAQ: IMRN) reported continued unaudited sales growth for Travelan® in H1 FY26 with global H1 sales of AUD$4.2 million, up 5% on the prior comparative period. Key regional results included Australia H1 AUD$3.3 million, +13%; USA H1 AUD$0.9 million, +17%; and Canada H1 AUD$56 thousand, -85% while Canada Q2 recovered +191% quarter-on-quarter. Growth in Australia and the U.S. was attributed to expanded digital/social marketing, promotions, new store listings and increased travel; a one-off reduction in stock holdings from the merged Sigma Healthcare/Chemist Warehouse group offset some Australian gains. ProIBS® launched in Australia before Christmas and is listed with two of three major pharmacy wholesalers and five banner groups.